Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option. (8th October 2018)

• Record Type: Journal Article
• Authors: Clausznitzer, Diana; Pichardo‐Almarza, Cesar; Relo, Ana Lucia; van Bergeijk, Jeroen; van der Kam, Elizabeth; Laplanche, Loic; Benson, Neil; Nijsen, Marjoleen
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 7:Number 11(2018)
• Page Start: 759
• Page End: 770
• Publication Date: 2018-10-08
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12351
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract : Alzheimer disease (AD) is a devastating neurodegenerative disorder with high unmet medical need. Drug development is hampered by limited understanding of the disease and its driving factors. Quantitative Systems Pharmacology (QSP) modeling provides a comprehensive quantitative framework to evaluate the relevance of biological mechanisms in the context of disease and to predict the efficacy of novel treatments. Here, we report a QSP model for AD with a particular focus on investigating the relevance of dysregulation of cholesterol and sphingolipids. We show that our model captures the modulation of several biomarkers in subjects with AD, as well as the response to pharmacological interventions. We evaluate the impact of targeting the sphingosine‐1‐phosphate 5 receptor (S1PR5) as a potential novel treatment option for AD, and model predictions increase our confidence in this novel disease pathway. Future applications for the QSP model are in validation of further targets and identification of potential treatment response biomarkers.